Vanderbilt
AI tools have impressive potential in personalizing treatments, but doctors are concerned about bias, generalizability, and the lack of prospective validation.
All of Us Data Leads to New Genetic Variants, Disease Risk Contributors
A collection of papers has provided a look at findings from the All of Us Research Program's release of 245,388 clinical-grade genome sequences.
The researchers hope to reproduce in a prospective clinical trial the model's 70 percent to 80 percent accuracy for predicting immunotherapy response.
They are exploring a nicotine metabolite ratio that reflects variations in the CYP2A6 gene to gauge if it can ID patients who need more personalized smoking cessation interventions.
Alliance for Genomic Discovery Adds Major Biopharma Partners to Help Fund WGS-Based Biobank
Funding from AbbVie, Amgen, AstraZeneca, Bayer, and Merck will enable DeCode Genetics to sequence an additional 215,000 samples for the alliance.